Annexon (NASDAQ:ANNX) Insider Jamie Dananberg Sells 5,290 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,290 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the completion of the transaction, the insider owned 73,152 shares in the company, valued at $373,075.20. This represents a 6.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Annexon Stock Down 3.9%

NASDAQ ANNX traded down $0.20 on Friday, reaching $4.90. The company had a trading volume of 1,749,100 shares, compared to its average volume of 1,986,881. The stock has a market capitalization of $586.19 million, a P/E ratio of -3.48 and a beta of 1.17. The company’s fifty day moving average is $5.58 and its 200 day moving average is $3.94. Annexon, Inc. has a 52-week low of $1.28 and a 52-week high of $7.18.

Key Headlines Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ANNX shares. Chardan Capital assumed coverage on shares of Annexon in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $16.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Wells Fargo & Company boosted their price objective on Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Hedge Funds Weigh In On Annexon

Institutional investors and hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of Annexon by 13.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock valued at $100,000 after buying an additional 2,348 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its stake in Annexon by 0.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock valued at $1,790,000 after acquiring an additional 2,875 shares during the period. ProShare Advisors LLC raised its stake in Annexon by 21.7% in the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock valued at $124,000 after acquiring an additional 4,410 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its holdings in Annexon by 14.3% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $122,000 after purchasing an additional 5,000 shares during the last quarter.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.